Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Recruiting Phase 2 Trials for Oxaliplatin (DB00526)

IndicationStatusPhase
DBCOND0113388 (Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05651594Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction AdenocarcinomaTreatment